Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise ...

Boehringer Ingelheim and Click Therapeutics are restructuring their marketing deal for the software-based schizophrenia ...

Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 ...

Philips has issued a voluntary recall of software for its Trilogy Evo ventilator ser | Philips issued a voluntary recall of ...

A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...

J&J Medtech has launched the latest version of its pulsed ablation device after receiving CE Mark approval in Europe. The ...

Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung ...

After Medline pulled off a massive $6.26 billion IPO late last year, the company now finds itself facing serious concerns ...

When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...

Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 ...

Oncology biotech Akari Therapeutics has announced a partnership with WuXi XDC, an antibody-drug conjugate (ADC) development ...